![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, December 08, 2016 2:48:07 PM
You make it all sound so simple. Get rid of Nader and we are off to the races with an increase in SP and FDA approval. The fact is none of us are privy to the changing demands the FDA presents. The protocol for the Adjunct is quite restrictive. If it wasn't for Nader negotiating from 300 patients to 30 we'd most likely would have run out of time and $'s before fully enrolling the Trial.
"As we are enrolling people into the Cytodyn PRO140 study, one has experienced resistance in 2 of the 5 classes of current available HIV medications. And one MUST have at least 2 remaining medications that are still fully active".
For all the details relating to the protocol check out: https://clinicaltrials.gov/ct2/show/NCT02483078
Instead of being hung out to dry we will hit primary endpoint Q1 2017 for Adjunct and begin Mono this month - and the Mono trial will enroll in a flash because the protocol is much less restrictive and Charlie is talking it up creating a waiting list. That calls for his head???
My point is the current SP is independent of what is taking place with the advancement of Pro-140. If we fail to make that distinction, angst gets the better of our judgement and perception because everybody is under water with the current SP. Warrant backed raises apply short term downward pressure but are the best alternative to raise $'s. Unfortunately the shares that are purchased to obtain the warrant rights are dumped by most participants that are strictly limiting their exposure to very little or zero. That is why Nader will not do a reverse split. The SP would be devoured by the warrant holders still holding shares and will ultimately screw the investor that has real skin in the game.
Nader is not going to focus on short term SP - his primary goal is to get Pro-140 approved and challenge SOC within the BP HIV space creating leverage for a major multi-billion $ buyout. The fact is Nader is quite competent and will not be distracted from the task at hand.
He understands Adjunct approval is a stepping stone, a gateway to the big dance. Monotherapy is where Pro-140 can turn the HIV space upside down. I'm not interested in going backwards for a short term attempt to increase SP.
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM